Eribulin mesylate is under clinical development by Eisai and currently in Phase II for Malignant Fibrous Histiocytoma. According to GlobalData, Phase II drugs for Malignant Fibrous Histiocytoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Eribulin mesylate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Eribulin mesylate overview
Eribulin mesylate (E-7389, Halaven,Teceris) is a microtubule dynamics inhibitor belonging to the halichondrin class of antineoplastic agents. It is formulated as a solution for the intravenous route of administration. It is indicated for the treatment of patients with locally advanced or metastatic breast cancer and unresectable or metastatic liposarcoma (leiomyosarcoma) who have received a prior anthracycline-containing regimen. Halaven is also indicated for the treatment of patients with soft tissue sarcoma.
It is under development for the treatment of solitary firbous tumor, metastatic urothelial cell cancer, advanced metastatic breast cancer, recurrent or refractory solid tumors including lymphomas, glioblastoma, soft tissue sarcoma, relapsed/refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) and ewing sarcoma (EWS), triple negative breast cancer, angiosarcoma, synovial sarcoma, leiomyosarcoma, angiosarcoma, undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma, liposarcoma , fibrosarcoma, clear cell sarcoma, epithelioid sarcoma, malignant peripheral nerve sheath tumor, undifferentiated sarcoma, rhabdomyosarcoma, dermatofibrosarcoma protuberance, Ewing sarcoma/primary neuroectodermal tumor, desmoplastic circle Cellular tumor, inflammatory myofibroblastic sarcoma, malignant solitary fibroma and pregressive epitheloid hemangioendothelioma (EHE). It was also under development for the treatment of HER2 positive breast cancer, HER2 negative breast cancer, metastatic hormone refractory prostate cancer, ovarian cancer, uterine cancer and non-small cell lung cancer that has progressed following two or more prior treatment regimens and bladder cancer, transitional cell cancers of the urothelium including prostate, urethra, ureter, and renal pelvis cancers.
Eisai is a pharmaceutical company that discovers, develops, manufactures and markets pharmaceuticals, including prescription medicines, OTC drugs and generics. The company’s franchise areas in research include neurology and oncology. Eisai’s major products include Pariet/AcipHex, a proton pump inhibitor; Aricept, an anti-Alzheimer agent; perampanel, Halaven, an anti-cancer agent; Fycompa tablets for the treatment of epilepsy and peripheral neuropathy. Eisai has production plants in Japan, the UK, China, and India and laboratories in Japan, the US and the UK; operations in the Americas, Asia and Latin America, EMEA and Oceania with overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.
For a complete picture of Eribulin mesylate’s drug-specific PTSR and LoA scores, buy the report here.